• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how we’re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCE®
    • BRINSUPRI®
  • Responsibility

    Responsibility

    See how we’re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility in Action

    Our commitment to responsibility reflects the culture and purpose we live by every day.

    Visit our Responsibility site

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCE®
      BRINSUPRI®
  • Responsibility
    • Responsibility
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

Press Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Apr 7, 2014
    Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference

    Read more

  • Apr 2, 2014
    Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities

    Read more

  • Mar 26, 2014
    Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections
    Conference Call with Insmed Management and Clinical Trial Investigators Will be Held Today at 8:00 a.m. Eastern Time

    Read more

  • Mar 25, 2014
    Insmed to Announce Results From U.S. Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacteria Lung Infections

    Read more

  • Mar 6, 2014
    Insmed Reports 2013 Fourth Quarter and Full Year Financial Results

    Read more

  • Feb 19, 2014
    Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
    Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect

    Read more

  • Feb 10, 2014
    ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria

    Read more

  • Feb 4, 2014
    Insmed to Present at the Leerink Swann Global Healthcare Conference

    Read more

  • Feb 4, 2014
    Insmed to Present at the Leerink Swann Global Healthcare Conference

    Read more

  • Nov 5, 2013
    Insmed Reports Third Quarter 2013 Financial Results

    Read more

  • Nov 1, 2013
    Insmed Appoints David W.J. McGirr to Its Board of Directors

    Read more

  • Oct 23, 2013
    Insmed to Host Third Quarter 2013 Financial Results Conference Call on Tuesday, November 5, 2013

    Read more

  • Oct 15, 2013
    Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada

    Read more

  • Sep 15, 2013
    Insmed to Present at Leerink Swann Rare Disease Roundtable

    Read more

  • Sep 11, 2013
    Insmed Fortifies Global Patent Portfolio

    Read more

  • Sep 4, 2013
    Insmed to Participate in the Stifel Healthcare Conference 2013

    Read more

  • Aug 7, 2013
    Insmed to Participate in August Investor Conferences

    Read more

  • Aug 6, 2013
    Insmed Reports Second Quarter Financial Results

    Read more

  • Jul 31, 2013
    Insmed to Host Second Quarter 2013 Financial Results Conference Call on Tuesday, August 6, 2013

    Read more

  • Jul 29, 2013
    Insmed Appoints Christine Pellizzari as General Counsel and Corporate Secretary

    Read more

  • Jul 22, 2013
    Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares

    Read more

  • Jul 17, 2013
    Insmed Announces Pricing of Public Offering of Common Stock

    Read more

  • Jul 15, 2013
    Insmed Announces Proposed Public Offering of Common Stock

    Read more

  • Jul 8, 2013
    Insmed to Present at the 8th Annual JMP Securities Healthcare Conference

    Read more

  • Jul 1, 2013
    ARIKACE Meets Primary Endpoint of Non-Inferiority to TOBI in Phase 3 Clinical Trial in Europe and Canada to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
    ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections

    Read more

  • Jun 28, 2013
    Insmed to Join the Russell Global(R) and Russell 3000(R) Indexes

    Read more

  • Jun 28, 2013
    Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis

    Read more

  • May 14, 2013
    Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe

    Read more

  • May 13, 2013
    Insmed to Present at the UBS Global Healthcare Conference

    Read more

  • May 10, 2013
    Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

    Read more

  • May 7, 2013
    Insmed Reports First Quarter Financial Results

    Read more

  • May 1, 2013
    Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013

    Read more

  • Apr 18, 2013
    Insmed to Present at the 12th Annual Needham Healthcare Conference

    Read more

  • Apr 1, 2013
    Insmed Appoints Matthew Pauls as Chief Commercial Officer

    Read more

  • Mar 28, 2013
    ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria

    Read more

  • Mar 27, 2013
    Insmed to Present at Future Leaders in the Biotech Industry Conference

    Read more

  • Mar 18, 2013
    Insmed Reports Fourth Quarter and Full Year 2012 Financial Results

    Read more

  • Mar 11, 2013
    Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013

    Read more

  • Feb 26, 2013
    Insmed to Present at Two Upcoming Investor Conferences

    Read more

  • Feb 6, 2013
    Insmed to Present at Two Upcoming Healthcare Investor Conferences

    Read more

  • Dec 13, 2012
    Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference

    Read more

  • Nov 13, 2012
    Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment

    Read more

  • Nov 12, 2012
    Insmed To Present At Two Upcoming Investor Conferences

    Read more

  • Nov 7, 2012
    Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer

    Read more

  • Nov 7, 2012
    Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012

    Read more

  • Oct 24, 2012
    Insmed to Host 2012 Third Quarter Earnings Conference Call

    Read more

  • Sep 28, 2012
    Insmed Announces Pricing of Approximately $26 Million Direct Public Offering

    Read more

  • Aug 30, 2012
    Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference

    Read more

  • Aug 14, 2012
    Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference

    Read more

  • Aug 7, 2012
    Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012

    Read more

Show 5102550100 per page
  • «
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 16
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy ChoicesCookie Settings

© 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.